Biotech entity
All 1 tracked stories fall under one category: pharma. Amtagvi is most often covered alongside Fidelity National, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Amtagvi appears in 1 tracked Biotech story from February 23, 2026.
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Amtagvi is most often covered alongside Fidelity National, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Amtagvi appears in 1 tracked Biotech story from February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amtagvi. Shared-story counts are live from our verified record — not editorial picks.
Iovance Biotherapeutics is set to report Q4 2025 results, marking a full year of commercial operations for its breakthrough TIL therapy, Amtagvi. The update will be a critical indicator of the company's ability to scale complex cell therapy logistics and expand its market presence in oncology.
Amtagvi is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
